Neumora Therapeutics
(NASDAQ) NMRA
Neumora Therapeutics Financials at a Glance
Market Cap
$412.71M
Revenue (TTM)
$0.00
Net Income (TTM)
$236.30M
EPS (TTM)
$-1.46
P/E Ratio
-1.69
Dividend
$0.00
Beta (Volatility)
1.82 (High)
Dividend
$0.00
Beta (Volatility)
1.82 (High)
Price
$2.46
Volume
23,973
Open
$2.56
Price
$2.46
Volume
23,973
Open
$2.56
Previous Close
$2.46
Daily Range
$2.41 - $2.58
52-Week Range
$0.61 - $3.65
Dividend
$0.00
Beta (Volatility)
1.82 (High)
Price
$2.46
Volume
23,973
Open
$2.56
Previous Close
$2.46
Daily Range
$2.41 - $2.58
52-Week Range
$0.61 - $3.65
NMRA News
NMRA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Neumora Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
95
CEO
Paul L. Berns
Website
www.neumoratx.comHeadquarters
Watertown, DE 02472, US
NMRA Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-104%
Return on Capital
-2%
Return on Assets
-1%
Earnings Yield
-59.17%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$412.71M
Shares Outstanding
167.09M
Volume
23.97K
Short Interest
0.00%
Avg. Volume
1.63M
Financials (TTM)
Gross Profit
$0.00
Operating Income
$263.46M
EBITDA
$262.83M
Operating Cash Flow
$182.94M
Capital Expenditure
$0.00
Free Cash Flow
$182.94M
Cash & ST Invst.
$307.58M
Total Debt
$1.85M
Neumora Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$5.00M
N/A
Gross Margin
0.00%
N/A
Market Cap
$412.71M
N/A
Market Cap/Employee
$3.75M
N/A
Employees
110
N/A
Net Income
$56.76M
+21.8%
EBITDA
$55.98M
+26.8%
Quarterly Fundamentals
Net Cash
$171.00M
-49.5%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$267.00K
N/A
Short Term Debt
$256.00K
-90.7%
Return on Assets
-1.33%
N/A
Return on Invested Capital
-1.62%
N/A
Free Cash Flow
$46.65M
-39.3%
Operating Cash Flow
$46.63M
-39.3%